Workflow
司太立(603520) - 2022 Q1 - 季度财报
StarryStarry(SH:603520)2022-05-27 16:00

Financial Performance - The company's operating revenue for Q1 2022 was CNY 517,298,394.90, representing a year-on-year increase of 42.08%[5] - The net profit attributable to shareholders for the same period was CNY 80,240,225.00, reflecting a growth of 24.27% compared to the previous year[5] - The basic earnings per share (EPS) for Q1 2022 was CNY 0.33, an increase of 26.92% year-on-year[6] - Net profit for Q1 2022 was CNY 86,622,112.55, representing a 34.1% increase compared to CNY 64,606,088.08 in Q1 2021[21] - The total operating profit for Q1 2022 was CNY 41,867,475.82, a decrease of 49.7% compared to CNY 83,275,241.11 in Q1 2021[31] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 5,150,564,779.50, up 5.21% from the end of the previous year[6] - The total assets of the company reached CNY 5,150,564,779.50, up from CNY 4,895,377,815.83, marking an increase of approximately 5.2%[16] - The company's total liabilities increased to CNY 2,183,283,340.90, compared to CNY 2,061,807,076.72 in the previous year, reflecting a growth of approximately 5.9%[16] - Total liabilities as of Q1 2022 amounted to CNY 2,869,548,916.37, up from CNY 2,680,840,106.19 in the previous year[19] - The company's total liabilities rose to 1,948,839,913.77 RMB, compared to 1,683,561,845.05 RMB, indicating an increase of about 15.8%[29] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 93,672,558.25, a significant decrease of 723.35% compared to the previous year[5] - The net cash flow from operating activities was -93,672,558.25 RMB, compared to -11,377,018.57 RMB in the previous year, indicating a significant decline in operational performance[24] - Total cash inflow from investing activities was 161,645,907.27 RMB, while cash outflow was 230,846,829.59 RMB, resulting in a net cash flow of -69,200,922.32 RMB, an improvement from -140,563,364.35 RMB year-over-year[24] - Cash inflow from financing activities amounted to 519,777,628.70 RMB, with cash outflow of 320,256,685.34 RMB, leading to a net cash flow of 199,520,943.36 RMB, a recovery from -145,136,403.97 RMB in the previous year[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,771[12] - Total equity attributable to shareholders reached CNY 2,252,306,632.98, an increase from CNY 2,174,978,008.51 in Q1 2021[19] Expenses - The company reported a 75.12% increase in operating costs, primarily due to increased sales volume and rising raw material prices[10] - The company experienced a 106.95% rise in selling expenses, attributed to increased sales activities in Shanghai[10] - Research and development expenses for Q1 2022 were CNY 27,968,697.96, compared to CNY 24,812,028.35 in Q1 2021, reflecting a focus on innovation[19] - The company incurred financial expenses of CNY 2,195,161.43 in Q1 2022, a decrease from CNY 7,043,470.02 in Q1 2021[30] Current Assets - As of March 31, 2022, the total current assets of Zhejiang Sitaili Pharmaceutical Co., Ltd. amounted to CNY 2,183,283,340.90, an increase from CNY 2,061,807,076.72 in the previous year, reflecting a growth of approximately 5.9%[15] - The company's cash and cash equivalents stood at CNY 783,552,729.51, compared to CNY 775,740,000.41 as of December 31, 2021, indicating a slight increase[15] - Accounts receivable increased to CNY 639,897,913.77 from CNY 543,928,714.22, representing a growth of about 17.6% year-over-year[15] - The company's inventory decreased to CNY 492,994,623.71 from CNY 517,591,430.26, representing a decline of approximately 4.7%[16] Investment Income - The investment income surged by 936.80%, mainly due to the disposal of a subsidiary[10] - The company's long-term equity investments increased to 1,405,216,576.90 RMB from 1,383,214,555.16 RMB, reflecting a growth of about 1.6%[28]